Free Trial

Artelo Biosciences 5/13/2024 Earnings Report

Artelo Biosciences logo
$0.87 -0.01 (-0.91%)
As of 01:49 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Artelo Biosciences EPS Results

Actual EPS
-$0.78
Consensus EPS
-$1.05
Beat/Miss
Beat by +$0.27
One Year Ago EPS
N/A

Artelo Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Artelo Biosciences Announcement Details

Quarter
Time
Before Market Opens

Conference Call Resources

Remove Ads

Artelo Biosciences Earnings Headlines

Artelo Biosciences (ARTL) to Release Earnings on Monday
Elon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to Mars
Musk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to help build human colonies on the Red Planet. And here on Earth? Optimus is about to change everything.
Artelo Biosciences announces new data on ART12.11
See More Artelo Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Artelo Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Artelo Biosciences and other key companies, straight to your email.

About Artelo Biosciences

Artelo Biosciences (NASDAQ:ARTL), a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

View Artelo Biosciences Profile

More Earnings Resources from MarketBeat